menu
    • menu
    [{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"CAR-NK cell therapies","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Sofinnova Partners"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"CAT-248","moa":"CD70","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Allogeneic CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ University of Minnesota","highestDevelopmentStatusID":"2","companyTruncated":"Catamaran Bio \/ University of Minnesota"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"IL-15","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CAT-248","moa":"CD70","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Not Applicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Catamaran Bio"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"OmniaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Catamaran Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Catamaran Bio

    Menu

    Catamaran Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : OmniaBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Catamaran Bio Selects Omniabio As Partner To Develop And Manufacture Allogeneic CAR-NK Cell Therapies

                            Details : The partnership will enable the development and manufacturing of Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors.

                            Brand Name : Undislcosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 14, 2023

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : OmniaBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

                            Details : CAT-248 is a CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70, an IL-15 cytokine, a TME-switch, and the elimination of CD70 expression to enable scalabl...

                            Brand Name : CAT-248

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAT-248

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR‑NK Cell Therapies to Treat Solid Tumor...

                            Details : CAT-248 is company's off-the-shelf CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been modified as an optimized CAR that targets CD70 and an IL-15 cytokine that promotes persistence and enhanced NK cell activity.

                            Brand Name : CAT-248

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : CAT-248

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid T...

                            Details : CAR-NK cells engineered with this TGFβ DNR demonstrated reduction of downstream TGFβactivity as shown by >90% reduction of SMAD2 phosphorylation (a downstream signal of TGFβ activity) even at supraphysiological doses of TGFβ.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 16, 2022

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAT-179

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Solid Tumors

                            Details : CAT-179 has been engineered with three functional modifications: an optimized CAR that targets HER2, an IL-15 cytokine that promotes persistence and enhanced NK cell activity, and a TME-switch that neutralizes effects of TGFβ immunosuppressive found in ...

                            Brand Name : CAT-179

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : CAT-179

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAT-179

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT‑179, a HER2-targeted ...

                            Details : CAT-179 was efficiently engineered (45% CAR+) from donor-derived NK cells using non-viral TcBuster transposon system, incorporating a multi-cistronic cargo containing HER2 CAR, IL15, and TGFβ dominant-negative receptor (TGFβ DNR).

                            Brand Name : CAT-179

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : CAT-179

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : University of Minnesota

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Catamaran Bio Expands Collaboration for CAR-NK Cell Engineering with the University of Minnesota and Secures a...

                            Details : This expanded collaboration and license shows the commitment to develop and integrate the most advanced technologies for manufacturing of allogeneic CAR-NK cell therapies, and will optimize the TcBuster transposon system which has been integrated into TA...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 14, 2022

                            Lead Product(s) : Allogeneic CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : University of Minnesota

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAT-179

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Catamaran Bio to Present Preclinical Efficacy Data on Allogeneic Solid Tumor CAR-NK Program at AACR Annual Mee...

                            Details : CAT-179, been engineered with three functional modification: an optimized CAR that target HER2, an IL-15 cytokine that promotes persistence and enhanced NK cell activity, and a TME-switch that neutralizes effects of TGFβ immunosuppressive signal found i...

                            Brand Name : CAT-179

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : CAT-179

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAT-248

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf CD70-Targeted CAR-NK Cell Therapy...

                            Details : The data support advancement of CAT-248, Catamaran’s lead CAR-NK cell therapy candidate, which is directed against CD70, a tumor antigen that is highly expressed on certain types of cancers including renal cell carcinoma, glioma, pancreatic cancer, and...

                            Brand Name : CAT-248

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 13, 2021

                            Lead Product(s) : CAT-248

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Catamaran Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-NK cell therapies

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Sofinnova Partners

                            Deal Size : $42.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Catamaran Bio Launches with $42 Million Financing to Develop Off the Shelf CAR-NK Cell Therapies to Treat Soli...

                            Details : Proceeds will be used to advance the company’s two lead chimeric antigen receptor (CAR)-NK cell therapy programs and will expand the company’s TAILWIND™ Platform.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 23, 2020

                            Lead Product(s) : CAR-NK cell therapies

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Sofinnova Partners

                            Deal Size : $42.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth